Skip to main content
Top
Published in: Pituitary 6/2020

01-12-2020 | Pituitary Adenoma

Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly

Authors: Elena V. Varlamov, Matthew D. Wood, Joao Prola Netto, Jaclyn Thiessen, Jung Kim, Dawn Shao Ting Lim, Christine G. Yedinak, Swechya Banskota, Justin S. Cetas, Maria Fleseriu

Published in: Pituitary | Issue 6/2020

Login to get access

Abstract

Purpose

To investigate demographic, imaging and laboratory characteristics, and treatment outcomes of acromegaly patients who have bihormonal (BA) growth hormone (GH) and prolactin (PRL) immunoreactive adenomas compared to patients who have densely granulated GH adenomas (DGA) and sparsely granulated GH adenomas (SGA).

Methods

Retrospective review of single-center surgically treated acromegaly patients; pathology was analyzed by a single neuropathologist using 2017 WHO criteria. Preoperative magnetic resonance imaging was assessed to evaluate tumor size, cystic component, invasion and T2 signal intensity.

Results

Seventy-seven patients; 19 BA (9 mammosomatotroph and 10 mixed GH and PRL adenomas) were compared with 30 DGA, and 28 SGA. Patients with BA were older than SGA (49.6 vs 38.5 years, p = 0.035), had a higher IGF-1 index (3.3 vs 2.3, p = 0.040) and tumors were less frequently invasive (15.8% vs 57.1%, p = 0.005). BA more frequently had a cystic component on MRI than both SGA and DGA (52.6% vs 14.3%, and 22%, p = 0.005 and 0.033, respectively). When all histological types were combined, biochemical remission postoperatively was more common in non-cystic than cystic tumors (50% vs 22.5%, p = 0.042). Somatostatin receptor ligand response rate was 66.7%, 90.9% and 37.5% in BA, DGA and SGA patients, respectively (p = 0.053).

Conclusion

Imaging characteristics are an increasingly important adenoma behavior determinant. An adenoma cystic component may suggest that a GH adenoma is a BA. Cystic tumors exhibited lower rates of surgical remission in this series; therefore, optimized individual patient treatment is needed, as patients could be candidates for primary medical treatment.
Appendix
Available only for authorised users
Literature
4.
go back to reference Lloyd R, Osamura R, Klöppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. International Agency for Research on Cancer, Lyon Lloyd R, Osamura R, Klöppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, 4th edn. International Agency for Research on Cancer, Lyon
17.
go back to reference Bonneville J-F, Bonneville F, Cattin F, Nagi S (2016) MRI of the pituitary gland. Springer International Publishing, ChamCrossRef Bonneville J-F, Bonneville F, Cattin F, Nagi S (2016) MRI of the pituitary gland. Springer International Publishing, ChamCrossRef
23.
go back to reference Horvath E, Kovacs K (1974) Misplaced exocytosis. Distinct ultrastructural feature in some pituitary adenomas. Arch Pathol 97(4):221–224PubMed Horvath E, Kovacs K (1974) Misplaced exocytosis. Distinct ultrastructural feature in some pituitary adenomas. Arch Pathol 97(4):221–224PubMed
Metadata
Title
Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly
Authors
Elena V. Varlamov
Matthew D. Wood
Joao Prola Netto
Jaclyn Thiessen
Jung Kim
Dawn Shao Ting Lim
Christine G. Yedinak
Swechya Banskota
Justin S. Cetas
Maria Fleseriu
Publication date
01-12-2020
Publisher
Springer US
Published in
Pituitary / Issue 6/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-020-01075-7

Other articles of this Issue 6/2020

Pituitary 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.